异基因造血细胞移植后复发淋巴瘤的PD-1阻断治疗:高缓解率但移植物抗宿主病频发
这项多中心回顾性分析纳入31例异基因造血细胞移植后复发接受抗PD-1单克隆抗体的淋巴瘤患者,其中29例为经典型霍奇金淋巴瘤。30例可评估患者总缓解率为77%,但17例(55%)出现治疗新发移植物抗宿主病,其中9例为III-IV级急性或重度慢性,且多难治。作者认为PD-1阻断在移植后复发经典型霍奇金淋巴瘤中似乎高效,但常并发快速起病的严重难治性移植物抗宿主病,不能在临床试验外常规推荐。
要点
- 移植后复发淋巴瘤抗PD-1治疗总缓解率77%(15例完全缓解、8例部分缓解,30例可评估)。
- 17例(55%)出现治疗新发移植物抗宿主病(6例急性、4例重叠、7例慢性),中位起病分别为1、2、2剂后。
- 17例移植物抗宿主病中仅2例对治疗达完全缓解,14例需≥2种全身治疗;8例(26%)死亡与新发移植物抗宿主病相关。
核心结论
- PD-1阻断在异基因造血细胞移植后复发经典型霍奇金淋巴瘤患者中似乎高度有效,但常并发快速起病的严重且治疗难治性移植物抗宿主病。
- PD-1阻断在异基因造血细胞移植后应进一步研究,但不能在临床试验外常规推荐使用。
研究设计与样本
- 多中心回顾性分析,纳入31例异基因造血细胞移植后复发接受抗PD-1单克隆抗体治疗的淋巴瘤患者。
- 29例(94%)为经典型霍奇金淋巴瘤,27例在移植后及抗PD-1治疗前接受过至少1种挽救治疗。
- 首次抗PD-1给药后中位随访428天(范围133-833天)。
主要发现
- 30例可评估患者总缓解率为77%,其中15例完全缓解、8例部分缓解。
- 末次随访时31例中11例进展,21例(68%)存活,8例(26%)死亡与新发移植物宿主病相关。
- 17例(55%)在抗PD-1启动后出现治疗新发移植物抗宿主病:6例急性、4例重叠、7例慢性,中位起病分别在1、2、2剂后。
- 移植物抗宿主病严重程度为III-IV级急性或重度慢性者9例;17例中仅2例对移植物抗宿主病治疗达完全缓解,14例需至少2种全身治疗。
临床怎么用
- 作者认为PD-1阻断在移植后复发经典型霍奇金淋巴瘤中似乎高度有效,但常并发快速起病的严重难治性移植物抗宿主病。
- 作者结论指出PD-1阻断在异基因造血细胞移植后应进一步研究,但不能在临床试验外常规推荐使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Given the limited treatment options for relapsed lymphoma post-allogeneic hematopoietic cell transplantation (post-allo-HCT) and the success of programmed death 1 (PD-1) blockade in classical Hodgkin lymphoma (cHL) patients, anti-PD-1 monoclonal antibodies (mAbs) are increasingly being used off-label after allo-HCT. To characterize the safety and efficacy of PD-1 blockade in this setting, we conducted a multicenter retrospective analysis of 31 lymphoma patients receiving anti-PD-1 mAbs for relapse post-allo-HCT. Twenty-nine (94%) patients had cHL and 27 had ≥1 salvage therapy post-allo-HCT and prior to anti-PD-1 treatment. Median follow-up was 428 days (range, 133-833) after the first dose of anti-PD-1. Overall response rate was 77% (15 complete responses and 8 partial responses) in 30 evaluable patients. At last follow-up, 11 of 31 patients progressed and 21 of 31 (68%) remain alive, with 8 (26%) deaths related to new-onset graft-versus-host disease (GVHD) after anti-PD-1. Seventeen (55%) patients developed treatment-emergent GVHD after initiation of anti-PD-1 (6 acute, 4 overlap, and 7 chronic), with onset after a median of 1, 2, and 2 doses, respectively. GVHD severity was grade III-IV acute or severe chronic in 9 patients. Only 2 of these 17 patients achieved complete response to GVHD treatment, and 14 of 17 required ≥2 systemic therapies. In conclusion, PD-1 blockade in relapsed cHL allo-HCT patients appears to be highly efficacious but frequently complicated by rapid onset of severe and treatment-refractory GVHD. PD-1 blockade post-allo-HCT should be studied further but cannot be recommended for routine use outside of a clinical trial.
引用
- Haverkos BM, Abbott D, Hamadani M, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017. PMID: 28468799. doi:10.1182/blood-2017-01-761346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。